Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002204 | 1.00 | NR1H4 (0.73) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL12572018 | 1.00 | NR1H4 (0.73) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL2005313 | 0.93 | NR1H4 (0.85) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL2005033 | 0.92 | NR1H4 (0.86) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL12572013 | 0.92 | NR1H4 (0.86) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL2002724 | 0.92 | NR1H4 (0.86) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL4337574 | 0.87 | NR1H4 (0.65) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL2004177 | 0.86 | NR1H4 (0.73) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL2000682 | 0.85 | NR1H4 (0.72) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL2006445 | 0.85 | NR1H4 (1.00) | NR1H4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960552-B2 | 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-2-quinolinecarboxylic acid and the potassium salt; antidiabetic agents; improved glucose tolerance and decreased insulin resistance | GLAXOSMITHKLINE LLC (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100120775-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2079307-A2 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120775-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885CYP1A2 163/4885CYP2C9 347/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885CYP1A2 163/4885CYP2C9 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.